ASCO: Empty-handed AZ seeks attention for pipeline amid oncology frenzy
This article was originally published in Scrip
Executive Summary
AstraZeneca is distracting attention from its lack of Phase III fireworks at this year's ASCO meeting by trumpeting the progression of three of its cancer products into late-stage trials. But its excitement seems a little premature: recruitment has only begun for just one of these; the other two studies won't actually start until later this year.